Aerie CEO Anido Talks War Rooms, FDA, Rhopressa, Roclatan, and Getting Along with the Neighbors

Rhopressa FDA approval

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 159″]

Aerie Pharmaceuticals scored an impressive win at the recent FDA advisory panel, getting a thumbs up for the approval of Rhopressa. In this interview, CEO & Chairman Vince Anido explains how Aerie plans to move forward with its lead glaucoma product. He also tells how its new drug-delivery technology will fit into its plans. In addition, we get an update on the late-stage trials of Roclatan.

Do You Have

A STORY TO TELL?

If you’d like to be considered as a guest on a future episode of the OIS podcast, please complete the application today.

Meet Our Hosts

Ehsan Sadri
ehsan sadri
Firas Rahhal
Firas Rahhal, MD
Paul Karpecki
Paul Karpecki
Robert Rothman
Robert Rothman
Subscribe

ON iTUNES

Don't miss an episode. Join the conversation by visiting our podcast channel on iTunes today and subscribe. It's fast and free!

STAY UP TO DATE WITH OIS

Get the Latest News, Podcasts and Videos.